FDE DIAGNOSTIC ARCHITECTURE

The Diagnostic Brief Blueprint

Under Phase 0, VXS delivers structured risk mapping using the 7-module blueprint below. Switch between the Interactive Preview Simulator to view realistic failure diagnoses, and the Raw Markdown Blueprint to copy the diagnostic schema.

Scan ID FDE-20260529-001
Product Type Probiotic Beverage
Current Stage Bench prototype
Target Process Hot-fill / pasteurization
VXS DIAGNOSTIC DISCLAIMER: This brief identifies potential industrial risk patterns based on submitted parameters. It is a protocol-assisted review of physical, chemical, and biological system boundaries. It does not replace laboratory scale-up testing, regulatory reviews, process engineering validation, safety testing, or medical/nutritional claim audits.
02 / TPI-LITE RISK SCORE
78/100
HIGH CONFIDENCE
Systemic Stress Level High Risk Range
0 (Stable) 45 (Limit) 70 (Critical) 100 (Collapse)

Confidence assessment driven by complete processing thermal window parameters. High thermal input conflicts with active system thermodynamic boundaries.

03 / T-B-C-M-S RISK LAYER MAPPING
Layer Risk Level Observed Mismatch Signal Critical Physical Unknown
04 / DETECTED FAILURES & RISK CODES
05 / PROCESS COMPATIBILITY DIAGNOSTICS
06 / RECOMMENDED VERIFICATION STEPS
07 / DATA HANDLING PROTOCOL REFERENCE

This diagnostic review was produced from limited physical and chemical parameters supplied by the client. No exact proprietary ingredient ratios, supplier names, or brand identities were requested or processed. Pattern-level signature logging has been restricted to anonymized aggregates in compliance with selected intake directives.

# VXS Diagnostic Brief Template
## Formula Diagnostic Engine / Phase 0

**Scan ID**: FDE-YYYYMMDD-XXX  
**Product Type**: [Functional beverage / supplement / etc.]  
**Stage**: [Bench / pre-pilot / pilot planned / etc.]  
**Target Scale**: [Scale band]  
**Review Type**: Protocol-assisted manual review  
**Disclaimer**: This brief is a structured risk map. It is not a safety review, regulatory review, medical claim review, laboratory test, or guarantee of scale-up success.

---

## 01 / System Snapshot

| Parameter | User Input |
| --- | --- |
| Product type | [input] |
| Current stage | [input] |
| Target scale | [input] |
| Primary process | [input] |
| Ingredient count range | [input] |
| Sensitive system flags | [input] |
| Main concern | [input] |

---

## 02 / TPI-Lite Risk Score

**Preliminary Score Band**: [0-25 / 26-45 / 46-65 / 66-85 / 86-100]  
**Confidence Level**: [Low / Medium / High]  
**Reason for Confidence Level**: [data completeness, stage, missing parameters]

Interpretation:
[3-5 sentences. Neutral and technical. No fear-based language.]

---

## 03 / T-B-C-M-S Risk Layer Mapping

| Layer | Risk Status | Observed Signal | Critical Unknown |
| --- | --- | --- | --- |
| T / Thermodynamic | [Low / Medium / High / Unknown] | [signal] | [unknown] |
| B / Biological | [Low / Medium / High / Unknown] | [signal] | [unknown] |
| C / Chemical | [Low / Medium / High / Unknown] | [signal] | [unknown] |
| M / Mechanical | [Low / Medium / High / Unknown] | [signal] | [unknown] |
| S / Stability | [Low / Medium / High / Unknown] | [signal] | [unknown] |

---

## 04 / Detected Risk Codes

Example:
- `T-01 / Thermal Degradation`: [why it may apply]
- `B-01 / Living System Scale Fragility`: [why it may apply]
- `S-02 / Moisture Migration`: [why it may apply]

Only include codes that can be supported by submitted data.

---

## 05 / Process Compatibility Notes

Summarize where the product system and process route may diverge:
- [Compatibility note 1]
- [Compatibility note 2]
- [Compatibility note 3]

---

## 06 / Recommended Verification Steps

These are next validation questions, not final solutions.
1. [Validation step]
2. [Validation step]
3. [Validation step]
4. [Optional validation step]
5. [Optional validation step]

---

## 07 / Data Handling Note

This diagnostic brief was produced from limited parameters supplied by the user. No full formula or exact ratios were required. Pattern-level retention is governed by the consent selected during intake.